Electromed, Inc. — Fiscal 2026 Earnings Summary

Financial Performance

• Net revenue increased 11.6% year-over-year to $19.4 million in Q4 FY 2026, compared to $17.4 million in Q4 FY 2025.
• Net revenue increased 15.3% year-over-year to $73.8 million for full-year FY 2026, compared to $64.0 million in FY 2025.
• Operating income increased 25.8% to $3.8 million (19.7% of net revenues) in Q4 FY 2026, compared to $3.0 million (17.5% of net revenues) in Q4 FY 2025.
• Operating income increased 43.7% to $13.9 million (18.8% of net revenues) for full-year FY 2026, compared to $9.7 million (15.1% of net revenues) in FY 2025.
• Net income increased 54.3% to $3.4 million ($0.39 diluted EPS) in Q4 FY 2026, compared to $2.2 million ($0.25 diluted EPS) in Q4 FY 2025.
• Net income was $11.3 million ($1.30 diluted EPS) for full-year FY 2026, compared to $7.5 million ($0.85 diluted EPS) in FY 2025.
• Gross profit increased to $15.3 million (78.7% margin) in Q4 FY 2026 from $13.6 million (78.3% margin) in Q4 FY 2025.
• Gross profit increased to $57.9 million (78.5% margin) for full-year FY 2026 from $50.0 million (78.1% margin) in FY 2025.
• SG&A expenses were $11.1 million (up 8.3%) in Q4 FY 2026 and $42.7 million (up 8.7%) for full-year FY 2026, driven by increased personnel in sales, support, marketing, and reimbursement teams.
• Cash provided by operations totaled $9.7 million in FY 2026, compared to $11.4 million in FY 2025.
• As of June 30, 2026, the company held $20.5 million in cash, $29.8 million in accounts receivable, and no debt.
• Working capital was $45.1 million and total shareholders' equity was $54.0 million as of June 30, 2026.

Business Segments and Product Lines

• Direct homecare revenue increased 15.2% to $17.7 million in Q4 FY 2026 and 16.3% to $66.6 million for full-year FY 2026, driven by increased sales representatives, higher productivity, and higher net revenue per approval.
• Non-homecare revenue grew to $7.2 million in FY 2026 (up 6.7% from $6.7 million), primarily due to increased distributor and hospital revenue.
• The company averaged 58 homecare field sales representatives in FY 2026, with revenue per representative of $1,145,000, exceeding the target range of $1,000,000 to $1,100,000.
• The company noted strategic investments in sales force, systems, and bronchiectasis market development initiatives.

Other Key Points

• Electromed repurchased $3.9 million of its common stock throughout FY 2026.
• The company marked its 15th consecutive quarter of year-over-year revenue and profit growth.
• Operating margin increased more than 370 basis points over FY 2025.
• Electromed was recognized as one of Minnesota's fastest-growing public companies.
• The company has approximately 800,000 diagnosed bronchiectasis patients identified as potential beneficiaries for SmartVest® therapy.
• Conference call and webcast details were provided for August 25, 2026, at 5:00 p.m. Eastern Time.
• Forward-looking statements were included regarding reimbursement, regulatory approvals, competition, and economic conditions.